AZN · story · 26 October
AstraZeneca · 7 headlines from 7 outlets, on 26 October 2026.
Outlets report SAFFRON results and plans for FDA approval.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
TipRanks is the largest at 9.2, ahead of Yahoo Finance (9.2). GenomeWeb is the smallest at 7.5.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| TipRanks | 9.2 |
| Yahoo Finance | 9.2 |
| FirstWord Pharma | 8.7 |
| Fierce Pharma | 8.7 |
| Endpoints News | 8.3 |
| Stock Titan | 8.3 |
| GenomeWeb | 7.5 |
| Outlet | Headlines | Average tone |
|---|---|---|
| TipRanks | 1 | +9.2 |
| Yahoo Finance | 1 | +9.2 |
| FirstWord Pharma | 1 | +8.7 |
| Fierce Pharma | 1 | +8.7 |
| Endpoints News | 1 | +8.3 |
| Stock Titan | 1 | +8.3 |
| GenomeWeb | 1 | +7.5 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +9.2 | Phase III Tagrisso results announced, positive |
| +9.2 | Reduced progression and death risk in MET-driven lung cancer |
| +8.7 | Positive PFS and OS data for Tagrisso combo |
| +8.7 | Orpathys combo shows power after Tagrisso |
| +8.3 | Two-pill pairing could lengthen Tagrisso's useful life against lung cancer. |
| +8.3 | Median survival rose by close to five months with the combination. |
| +7.5 | Pursuing FDA approval for Tagrisso combination |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.